Ignite Creation Date:
2025-12-25 @ 4:04 AM
Ignite Modification Date:
2026-01-17 @ 1:02 AM
Study NCT ID:
NCT01100502
Status:
COMPLETED
Last Update Posted:
2021-05-14
First Post:
2010-04-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Sponsor:
Seagen Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-04-30
Start Date Type:
ACTUAL
Primary Completion Date:
2014-08-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-04-27
Completion Date Type:
ACTUAL
First Submit Date:
2010-04-06
First Submit QC Date:
None
Study First Post Date:
2010-04-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2015-07-31
Results First Submit QC Date:
None
Results First Post Date:
2015-11-11
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-04-22
Last Update Post Date:
2021-05-14
Last Update Post Date Type:
ACTUAL